File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Sofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with Chronic Genotype 6 Hepatitis C Virus Infection: integrated analysis of Phase 2 and Phase 3 studies

TitleSofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with Chronic Genotype 6 Hepatitis C Virus Infection: integrated analysis of Phase 2 and Phase 3 studies
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2015
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 761A, abstract no. 1120 How to Cite?
AbstractINTRODUCTION: Chronic HCV infection is endemic in South East Asia with HCV genotype 6 (GT6) accounting for 18-49% of those infected. In the US and Canada, nearly one-third of immigrants from Southeast Asia with HCV are infected with GT6. Few studies have examined the efficacy and safety of direct acting antiviral (DAA) regimens in GT6 infected patients. The aim of this integrated analysis was to characterize the efficacy and safety of sofosbuvir (SOF)-based regimens in patients with chronic GT6 HCV infection. METHODS: GT6 infected subjects were identified in 5 studies (ATOMIC, NEUTRINO, GS-US-334-0115, ELECTRON2, GS-US-337-0131) and are included in this analysis. Treatment-naïve or treatment-experienced patients received SOF+RBV±Peg-IFNα or ledipasvir (LDV)/SOF for 12-24 weeks. The primary efficacy endpoint in all studies was SVR12. RESULTS: A total of 52 subjects with GT6 HCV infection were identified. The majority were treatment-naïve (94%), Asian (81%), male (58%), and had IL28B CC alleles (81%). The mean age was 50 years (range 26-76) and 10% had cirrhosis. GT6 subtypes included 6a, 6a/b, 6c-1, 6e, 6g, 6j, 6l, 6m, 6o, 6p, 6q, and 6r. The table below presents SVR12 by regimen. One subject in ELECTRON2 withdrew consent after receiving 8 weeks of LDV/SOF and relapsed with the emergent NS5B RAV S282T. All remaining 51 patients achieved SVR12, including 100% (3/3) experienced and 100% (5/5) cirrhotics. CONCLUSIONS: SOF+RBV±Peg-IFNα and LDV/SOF regimens are well-tolerated and highly effective in patients with chronic GT6 HCV infection including those who are treatment experienced and have compensated cirrhosis. These regimens provide multiple therapeutic options for consideration when evaluating optimal therapy for individual patients with chronic GT6 HCV infection. (diagram see journal abstracts)
DescriptionPoster Session 2: Hepatitis C: Therapeutics (Approved Agents): no. 1120
This FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015
Persistent Identifierhttp://hdl.handle.net/10722/226667
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752

 

DC FieldValueLanguage
dc.contributor.authorGane, EJ-
dc.contributor.authorChuang, WL-
dc.contributor.authorHassanein, TI-
dc.contributor.authorKowdley, KV-
dc.contributor.authorLawitz, E-
dc.contributor.authorGao, B-
dc.contributor.authorMo, H-
dc.contributor.authorHyland, RH-
dc.contributor.authorYang, JC-
dc.contributor.authorDe-Oertel, S-
dc.contributor.authorBrainard, DM-
dc.contributor.authorKnox, SJ-
dc.contributor.authorMcHutchison, JG-
dc.contributor.authorLai, CL-
dc.contributor.authorChan, HLY-
dc.date.accessioned2016-06-22T02:14:55Z-
dc.date.available2016-06-22T02:14:55Z-
dc.date.issued2015-
dc.identifier.citationThe 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD Liver Meeting 2015), San Francisco, CA., 13-17 November 2015. In Hepatology, 2015, v. 62 suppl. S1, p. 761A, abstract no. 1120-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/226667-
dc.descriptionPoster Session 2: Hepatitis C: Therapeutics (Approved Agents): no. 1120-
dc.descriptionThis FREE journal suppl. entitled: Special Issue: The 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015-
dc.description.abstractINTRODUCTION: Chronic HCV infection is endemic in South East Asia with HCV genotype 6 (GT6) accounting for 18-49% of those infected. In the US and Canada, nearly one-third of immigrants from Southeast Asia with HCV are infected with GT6. Few studies have examined the efficacy and safety of direct acting antiviral (DAA) regimens in GT6 infected patients. The aim of this integrated analysis was to characterize the efficacy and safety of sofosbuvir (SOF)-based regimens in patients with chronic GT6 HCV infection. METHODS: GT6 infected subjects were identified in 5 studies (ATOMIC, NEUTRINO, GS-US-334-0115, ELECTRON2, GS-US-337-0131) and are included in this analysis. Treatment-naïve or treatment-experienced patients received SOF+RBV±Peg-IFNα or ledipasvir (LDV)/SOF for 12-24 weeks. The primary efficacy endpoint in all studies was SVR12. RESULTS: A total of 52 subjects with GT6 HCV infection were identified. The majority were treatment-naïve (94%), Asian (81%), male (58%), and had IL28B CC alleles (81%). The mean age was 50 years (range 26-76) and 10% had cirrhosis. GT6 subtypes included 6a, 6a/b, 6c-1, 6e, 6g, 6j, 6l, 6m, 6o, 6p, 6q, and 6r. The table below presents SVR12 by regimen. One subject in ELECTRON2 withdrew consent after receiving 8 weeks of LDV/SOF and relapsed with the emergent NS5B RAV S282T. All remaining 51 patients achieved SVR12, including 100% (3/3) experienced and 100% (5/5) cirrhotics. CONCLUSIONS: SOF+RBV±Peg-IFNα and LDV/SOF regimens are well-tolerated and highly effective in patients with chronic GT6 HCV infection including those who are treatment experienced and have compensated cirrhosis. These regimens provide multiple therapeutic options for consideration when evaluating optimal therapy for individual patients with chronic GT6 HCV infection. (diagram see journal abstracts)-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleSofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with Chronic Genotype 6 Hepatitis C Virus Infection: integrated analysis of Phase 2 and Phase 3 studies-
dc.typeConference_Paper-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.authorityLai, CL=rp00314-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.28228-
dc.identifier.hkuros258608-
dc.identifier.hkuros258653-
dc.identifier.volume62-
dc.identifier.issuesuppl. S1-
dc.identifier.spage761A, abstract no. 1120-
dc.identifier.epage761A, abstract no. 1120-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats